Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Category 2

Growth Hormone (2)

hrp0082p2-d3-435 | Growth Hormone (2) | ESPE2014

First-year Growth Response to GH in Relation to Final Height Outcome in Prepubertal Children with Idiopathic GH Deficiency

Straetemans Saartje , Thomas Muriel , Tenoutasse Sylvie , De Schepper Jean , Rooman Raoul

Background: Several definitions of poor growth response to first-year GH treatment, have been proposed based on the observed response of a large group of patients.Objective and hypotheses: Since a complete compensation of the height deficit is expected in children with GH deficiency (GHD) treated with GH, we have studied the different parameters for the first-year growth response in relation to the adult height gain in prepubertal children with iGHD....

hrp0082p2-d3-436 | Growth Hormone (2) | ESPE2014

Reevaluation of GH Secretion During Puberty in Children Diagnosed as GH-deficient During Childhood

Ramaroli Diego , Maines Evelina , Piona Claudia Anita , Morandi Grazia , Gaudino Rossella , Antoniazzi Franco

Background: GH secretion increases physiologically during puberty and GH levels correlate with pubertal stage. Therefore, puberty is the most likely time for normalization of GH secretion in children with GHD. No studies have so far evaluated in children diagnosed as GH-deficient during childhood potential predictors of response to the reevaluation of GH secretion during puberty.Objective and hypotheses: The aim of our study is to establish and compare t...

hrp0082p2-d3-437 | Growth Hormone (2) | ESPE2014

Long-Term Effects of GH Replacement Therapy on Thyroid Function in GH Deficiency Children

Esposito Andrea , Donato Iolanda Di , Rezzuto Martina , Alfano Sara , Moracas Cristina , Capalbo Donatella , Salerno Mariacarolina

Background: Several studies have investigated the effects of GH replacement therapy (GHRT) on thyroid function in children with GH deficiency (GHD) leading to contrasting results. Indeed, GHRT has been reported to affect the peripheral metabolism of thyroid hormones, to alter TSH secretion by pituitary and to unmask secondary hypothyroidism.Objective and hypotheses: To evaluate long-term effects of GHRT on thyroid function in a large cohort of GHD childr...

hrp0082p2-d3-438 | Growth Hormone (2) | ESPE2014

Does Priming with Sex Steroids Before GH Stimulation Test Increase the Diagnosis of Normal GH Secretion in Short Children?

Soliman Ashraf , De sanctis Vincenzo , Elgaali Elkhansa , Ahmed Hannah , Sabt Aml , Nassar Randa

Introduction: There is still controversy for priming with sex steroid before GH testing.Objective and hypotheses: We studied GH response to stimulation in 92 children >9 years with idiopathic short stature (HtSDS −2). They were divided randomly into two groups. Children in group 1 (n=50) were primed with premarin in girls and testosterone in boys and those in group 2 were not primed (n=42). All children were tested using stand...

hrp0082p2-d3-439 | Growth Hormone (2) | ESPE2014

GH Dosing Patterns in Short Children Born Small for Gestational Age

Petit Isabelle Oliver , Blankenstein Oliver , Zdravkovic Dragan , Tonnes Pedersen Birgitte , Pournara Effie

Introduction: In Europe, GH is approved for short (height SDS <−2.5) children born small for gestational age (SGA) who fail to show catch-up growth by 4 years of age.Methods: This report analysed the patterns of GH dose used in everyday clinical practice based on short children born SGA enrolled in NordiNet® IOS, an observational study evaluating the long-term effectiveness and safety of Norditropin®. Average GH ...

hrp0082p2-d3-440 | Growth Hormone (2) | ESPE2014

Two-Year Data from a Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human GH, in Short Children Born Small for Gestational Age

Schwarz Hans-Peter , Birkholz-Walerzak Dorota , Szalecki Mieczyslaw , Walczak Mieczyslaw , Galesanu Corina , Metreveli David , Khan-Boluki Jasmin , Schuck Ellen

Background: Children born small for gestational age (SGA) are predisposed to metabolic abnormalities. While the therapeutic benefit of recombinant human growth hormone (rhGH) therapy in improving height is widely recognised, it can affect carbohydrate metabolism, potentially inducing diabetes.Objective and hypotheses: This ongoing, prospective study aims to evaluate the long-term safety and efficacy of Omnitrope® (somatropin) in children ...

hrp0082p2-d3-441 | Growth Hormone (2) | ESPE2014

Effects of Gender and Gestational Age on GH Treatment in Very Young Children Born Small for Gestational Age

Boguszewski Margaret , Lindberg Anders , Wollmann Hartmut A

Background: Children born small for gestational age (SGA) with poor growth during the first years of life often remain with short stature during childhood and as adults.Objective and hypotheses: To evaluate the effects of gender and gestational age (GA) on outcomes of GH treatment in very young children born SGA.Method: 620 short SGA children on GH treatment enrolled in KIGS (The Pfizer International Growth Database) were analysed:...

hrp0082p2-d3-442 | Growth Hormone (2) | ESPE2014

Two-Year Results from Patro Children, a Multi-Centre, Non-Interventional Study of the Long-Term Efficacy and Safety of Omnitrope® in Children Requiring GH Treatment

Pfaffle Roland , Kanumakala Shankar , Hoybye Charlotte , Kristrom Berit , Schuck Ellen , Zabransky Markus , Battelino Tadej , Colle Michel

Background: PATRO children is an international, open, longitudinal, noninterventional study of the long-term safety and efficacy of Omnitrope®, a biosimilar recombinant human GH (rhGH).Objective and hypotheses: The primary objective is to assess the long-term safety of Omnitrope®, particularly the diabetogenic potential of GH in short children born small for gestational age, the risk of malignancies, and potential risks of...

hrp0082p2-d3-443 | Growth Hormone (2) | ESPE2014

The Effect of Two Different GH Dosages on Final Height and Bone Geometry

Lupi Fiorenzo , Bozzola Mauro , Buzi Fabio , Longhi Silvia , Mascolo Amelia , Pilotta Alba , Porto Rossella , Ruffinazzi Giulia , Zattoni Valentina , Radetti Giorgio

Background: GH has a strong positive influence on bone stimulating both bone elongation and increase in size by enhancing the accrual of trabecular and cortical bone up to the attainment of peak bone mass in young adult.Aim of the study: We compared the effect of two different GH dosages on statural growth and bone geometry in two groups of GH-deficient children at final height. Data has been collected retrospectively from 1994 to 2013.<p class="abst...

hrp0082p2-d3-444 | Growth Hormone (2) | ESPE2014

Baseline Body Composition of Children with Short Stature Diagnosed for GH Deficiency

Matusik Pawel , Barylak Aleksandra , Cholewka Patrycja , Klesiewicz Marta , Klos Karolina , Stasiulewicz Martyna , Cetera Maria , Malecka-Tendera Ewa

Background: Severe GH deficiency (GHD) is associated with significant body composition abnormalities. However there is no data assessing initial body composition parameters in the children with partial GHD.Objective and hypotheses: Study objective was initial body composition assessment in the short stature children diagnosed for GHD.Method: 54 consecutively diagnosed for GHD short statured children (40 boys) in the mean age 10.83&...

hrp0082p2-d3-445 | Growth Hormone (2) | ESPE2014

GH Treatment to Final Height in Children with Idiopathic Short Stature: Evidence for an Early Therapy Initiation Effect

Hatziagapiou Kiriaki , Zosi Paraskevi , Karakaidos Dionisis , Kaiafa Eleftheria , Vlahou Thomais , Kanaris Likourgos , Kafalidis Georgios

Background: GH treatment aims to normalise growth, increasing growth velocity, thus helping patients achieve an adult height in the normal range for the general population and for their familial genetic potential.Objectives: To evaluate the efficacy of early replacement therapy with recombinant GH (rGH) in Caucasian pre-pubertal children treated for GH deficiency.Methods: Our study included 64 boys and 49 girls, diagnosed with part...

hrp0082p2-d3-446 | Growth Hormone (2) | ESPE2014

Evaluation of the Safety and Usability of FlexPro® 30 mg/3 ml, for the Delivery of Norditropin® in Patients Requiring GH Therapy

Fuchs Gitte Schoning , Wen Yanhong , Klinck Rasmus , Qvist Marianne , Kappelgaard Anne-Marie

Introduction: This test assessed the safety and usability of FlexPro® 30 mg/3 ml (Novo Nordisk A/S, Denmark), a pen-injector for injection of human GH in patients with GH deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS) and children born small for gestational age (SGA), and validated the instructions for use (IFU) and instructional video.Methods: Children with GHD/SGA or TS/NS, adult patients, caregivers of patients with GHD/S...

hrp0082p2-d3-447 | Growth Hormone (2) | ESPE2014

Efficacy, Adherence, and Cost Study According to Pathology and Treatment Devices in Children Treated with GHRH

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , Elizalde Miriam Miriam , Lorente-Blazquez Isabel , Minguez Cristina , Martinez-Martinez Carlos

Background: Currently there are three distinct groups of GH devices: single dose (JM), preloaded pen/vial (VM) systems and electronic devices (DE) autoinjector systems. The choice could determine a greater or lesser adherence and thus influence the final treatment efficacy.Objective: Comparison of the therapeutic efficacy as measured by growth rate (VC), IGF1 as a function of various clinical variables, indicating GH and device used.<p class="abstext...